| CAS No 2566-20-3 |
Glycine,N-[(phenylmethoxy)carbonyl]glycylglycyl-null |
Inquiry |
| CAS No 25613-60-9 |
3-Oxazolidinecarboxylicacid, 2,5-dioxo-4-(phenylmethyl)-, phenylmethyl ester, (4S)-null |
Inquiry |
| CAS No 25581-41-3 |
Furo[3,4-d]-1,3-dioxol-4(3aH)-one,dihydro-2,2-dimethyl-, (3aR,6aR)-null |
Inquiry |
| CAS No 25528-71-6 |
Cyclohexanepropanoicacid, a-amino-, hydrochloride (1:1), (aS)-null |
Inquiry |
| CAS No 25341-42-8 |
Cyclohexanepropanoicacid, a-[[(phenylmethoxy)carbonyl]amino]-, (aS)-null |
Inquiry |
| CAS No 25245-34-5 |
2-bromo-1,4-dimethoxybenzenenull |
Inquiry |
| CAS No 25235-85-2 |
4-Chloroindolenull |
Inquiry |
| CAS No 252049-08-4 |
Butanoic acid,2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-[[(phenylmethoxy)carbonyl]amino]-,(2S)-null |
Inquiry |
| CAS No 2516-34-9 |
cyclobutylaminenull |
Inquiry |
| CAS No 25137-01-3 |
(R)-Piperidine-3-carboxylic acid ethyl esternull |
Inquiry |
| CAS No 25137-00-2 |
(R)-(-)-Nipecotic acidnull |
Inquiry |
| CAS No 251317-00-7 |
D-Alanine,3-amino-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-null |
Inquiry |
| CAS No 251316-98-0 |
L-Alloisoleucine,N-[(9H-fluoren-9-ylmethoxy)carbonyl]-null |
Inquiry |
| CAS No 2506-41-4 |
2-(chloromethyl)naphthalenenull |
Inquiry |
| CAS No 250611-12-2 |
D-Phenylalanine,N-[(1,1-dimethylethoxy)carbonyl]-4-(1,1-dimethylethyl)-null |
Inquiry |
| CAS No 25029-33-8 |
L-arabino-Hexose,2-deoxy-null |
Inquiry |
| CAS No 24967-93-9 |
Chondroitin 4-sulfatenull |
Inquiry |
| CAS No 24915-95-5 |
Butanoic acid,3-hydroxy-, ethyl ester, (3R)-null |
Inquiry |
| CAS No 2491-06-7 |
N,N-Dimethylglycine hydrochloridenull |
Inquiry |
| CAS No 24830-94-2 |
D(-)-allo-Threoninenull |
Inquiry |
| CAS No 2481-09-6 |
S-T-butyl-L-cysteine hydrochloridenull |
Inquiry |
| CAS No 2480-93-5 |
L-Ornithine,N2-[(1,1-dimethylethoxy)carbonyl]-N5-[(phenylmethoxy)carbonyl]-null |
Inquiry |
| CAS No 24807-55-4 |
3-Nitro-1,2,4-triazolenull |
Inquiry |
| CAS No 2480-23-1 |
L-Valine, N-methyl-null |
Inquiry |
| CAS No 247564-62-1 |
Benzene,2-(chloromethyl)-1,3,5-trifluoro-null |
Inquiry |
